West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
1 S&P 500 Stock on Our Buy List and 2 Facing Headwinds
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.45%. June E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.44%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.72%. June E-mini S&P futures...
1 Cash-Heavy Stock on Our Buy List and 2 We Find Risky
3 Healthcare Stocks We Steer Clear Of
The Top 5 Analyst Questions From West Pharmaceutical Services’s Q1 Earnings Call
1 Mooning Stock with Competitive Advantages and 2 Facing Headwinds